FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2139560421> ?p ?o ?g. }

• W2139560421 endingPage "1091" @default.
• W2139560421 startingPage "1083" @default.
• W2139560421 abstract "Glutamate excitotoxicity might contribute to the pathophysiology of amyotrophic lateral sclerosis. In animal models, decreased excitatory aminoacid transporter 2 (EAAT2) overexpression delays disease onset and prolongs survival, and ceftriaxone increases EAAT2 activity. We aimed to assess the safety and efficacy of ceftriaxone for amyotrophic lateral sclerosis in a combined phase 1, 2, and 3 clinical trial.This three-stage randomised, double-blind, placebo-controlled study was done at 59 clinical sites in the USA and Canada between Sept 4, 2006, and July 30, 2012. Eligible adult patients had amyotrophic lateral sclerosis, a vital capacity of more than 60% of that predicted for age and height, and symptom duration of less than 3 years. In stages 1 (pharmacokinetics) and 2 (safety), participants were randomly allocated (2:1) to ceftriaxone (2 g or 4 g per day) or placebo. In stage 3 (efficacy), participants assigned to ceftriaxone in stage 2 received 4 g ceftriaxone, participants assigned to placebo in stage 2 received placebo, and new participants were randomly assigned (2:1) to 4 g ceftriaxone or placebo. Participants, family members, and site staff were masked to treatment assignment. Randomisation was done by a computerised randomisation sequence with permuted blocks of 3. Participants received 2 g ceftriaxone or placebo twice daily through a central venous catheter administered at home by a trained caregiver. To minimise biliary side-effects, participants assigned to ceftriaxone also received 300 mg ursodeoxycholic acid twice daily and those assigned to placebo received matched placebo capsules. The coprimary efficacy outcomes were survival and functional decline, measured as the slope of Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) scores. Analyses were by intention to treat. This study is registered with ClinicalTrials.gov, number NCT00349622.Stage 3 included 66 participants from stages 1 and 2 and 448 new participants. In total, 340 participants were randomly allocated to ceftriaxone and 173 to placebo. During stages 1 and 2, mean ALSFRS-R declined more slowly in participants who received 4 g ceftriaxone than in those on placebo (difference 0·51 units per month, 95% CI 0·02 to 1·00; p=0·0416), but in stage 3 functional decline between the treatment groups did not differ (0·09, -0·06 to 0·24; p=0·2370). No significant differences in survival between the groups were recorded in stage 3 (HR 0·90, 95% CI 0·71 to 1·15; p=0·4146). Gastrointestinal adverse events and hepatobiliary adverse events were more common in the ceftriaxone group than in the placebo group (gastrointestinal, 245 of 340 [72%] ceftriaxone vs 97 of 173 [56%] placebo, p=0·0004; hepatobiliary, 211 [62%] vs 19 [11%], p<0·0001). Significantly more participants who received ceftriaxone had serious hepatobiliary serious adverse events (41 participants [12%]) than did those who received placebo (0 participants).Despite promising stage 2 data, stage 3 of this trial of ceftriaxone in amyotrophic lateral sclerosis did not show clinical efficacy. The adaptive design allowed for seamless transition from one phase to another, and central venous catheter use in the home setting was shown to be feasible.National Institute of Neurological Disorders and Stroke." @default.
• W2139560421 created "2016-06-24" @default.
• W2139560421 creator A5039761392 @default.
• W2139560421 date "2014-11-01" @default.
• W2139560421 modified "2023-10-02" @default.
• W2139560421 title "Safety and efficacy of ceftriaxone for amyotrophic lateral sclerosis: a multi-stage, randomised, double-blind, placebo-controlled trial" @default.
• W2139560421 cites W1968533747 @default.
• W2139560421 cites W1972162063 @default.
• W2139560421 cites W1977124965 @default.
• W2139560421 cites W1998513792 @default.
• W2139560421 cites W2016575029 @default.
• W2139560421 cites W2018291666 @default.
• W2139560421 cites W2021542157 @default.
• W2139560421 cites W2025813837 @default.
• W2139560421 cites W2026376929 @default.
• W2139560421 cites W2040937200 @default.
• W2139560421 cites W2044448185 @default.
• W2139560421 cites W2062426105 @default.
• W2139560421 cites W2069106411 @default.
• W2139560421 cites W2073864172 @default.
• W2139560421 cites W2083204774 @default.
• W2139560421 cites W2085165928 @default.
• W2139560421 cites W2095011021 @default.
• W2139560421 cites W2096285630 @default.
• W2139560421 cites W2098237643 @default.
• W2139560421 cites W2104886236 @default.
• W2139560421 cites W2106868673 @default.
• W2139560421 cites W2107132663 @default.
• W2139560421 cites W2108381339 @default.
• W2139560421 cites W2109420812 @default.
• W2139560421 cites W2113575093 @default.
• W2139560421 cites W2144536780 @default.
• W2139560421 cites W2147955864 @default.
• W2139560421 cites W2149497936 @default.
• W2139560421 cites W2151927746 @default.
• W2139560421 cites W2155221045 @default.
• W2139560421 cites W2161938104 @default.
• W2139560421 cites W2166915758 @default.
• W2139560421 cites W2167105734 @default.
• W2139560421 cites W2169587049 @default.
• W2139560421 cites W2171658613 @default.
• W2139560421 cites W2314689571 @default.
• W2139560421 cites W3179996438 @default.
• W2139560421 cites W4236884331 @default.
• W2139560421 cites W4254712695 @default.
• W2139560421 cites W4295180941 @default.
• W2139560421 cites W4319308344 @default.
• W2139560421 doi "https://doi.org/10.1016/s1474-4422(14)70222-4" @default.
• W2139560421 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4216315" @default.
• W2139560421 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25297012" @default.
• W2139560421 hasPublicationYear "2014" @default.
• W2139560421 type Work @default.
• W2139560421 sameAs 2139560421 @default.
• W2139560421 citedByCount "178" @default.
• W2139560421 countsByYear W21395604212014 @default.
• W2139560421 countsByYear W21395604212015 @default.
• W2139560421 countsByYear W21395604212016 @default.
• W2139560421 countsByYear W21395604212017 @default.
• W2139560421 countsByYear W21395604212018 @default.
• W2139560421 countsByYear W21395604212019 @default.
• W2139560421 countsByYear W21395604212020 @default.
• W2139560421 countsByYear W21395604212021 @default.
• W2139560421 countsByYear W21395604212022 @default.
• W2139560421 countsByYear W21395604212023 @default.
• W2139560421 crossrefType "journal-article" @default.
• W2139560421 hasAuthorship W2139560421A5039761392 @default.
• W2139560421 hasBestOaLocation W21395604212 @default.
• W2139560421 hasConcept C126322002 @default.
• W2139560421 hasConcept C142724271 @default.
• W2139560421 hasConcept C204787440 @default.
• W2139560421 hasConcept C27081682 @default.
• W2139560421 hasConcept C2776520383 @default.
• W2139560421 hasConcept C2779134260 @default.
• W2139560421 hasConcept C2780596555 @default.
• W2139560421 hasConcept C501593827 @default.
• W2139560421 hasConcept C535046627 @default.
• W2139560421 hasConcept C71924100 @default.
• W2139560421 hasConcept C86803240 @default.
• W2139560421 hasConcept C89423630 @default.
• W2139560421 hasConceptScore W2139560421C126322002 @default.
• W2139560421 hasConceptScore W2139560421C142724271 @default.
• W2139560421 hasConceptScore W2139560421C204787440 @default.
• W2139560421 hasConceptScore W2139560421C27081682 @default.
• W2139560421 hasConceptScore W2139560421C2776520383 @default.
• W2139560421 hasConceptScore W2139560421C2779134260 @default.
• W2139560421 hasConceptScore W2139560421C2780596555 @default.
• W2139560421 hasConceptScore W2139560421C501593827 @default.
• W2139560421 hasConceptScore W2139560421C535046627 @default.
• W2139560421 hasConceptScore W2139560421C71924100 @default.
• W2139560421 hasConceptScore W2139560421C86803240 @default.
• W2139560421 hasConceptScore W2139560421C89423630 @default.
• W2139560421 hasIssue "11" @default.
• W2139560421 hasLocation W21395604211 @default.
• W2139560421 hasLocation W21395604212 @default.
• W2139560421 hasLocation W21395604213 @default.
• W2139560421 hasLocation W21395604214 @default.
• W2139560421 hasLocation W21395604215 @default.
• W2139560421 hasOpenAccess W2139560421 @default.

• next